Sanara MedTech (SMTI) Set to Announce Quarterly Earnings on Wednesday

Sanara MedTech (NASDAQ:SMTI) will likely be announcing its Q3 2026 resultson Wednesday, November 11th. Analysts expect Sanara MedTech to announce earnings of $0.06 per share and revenue of $29.67 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:00 PM ET.

Sanara MedTech (NASDAQ:SMTI) last announced its earnings results on Tuesday, August 11th. The company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.03). Sanara MedTech had a negative net margin of 29.15% and a positive return on equity of 29.72%. The firm had revenue of $28.14 million for the quarter, compared to analysts’ expectations of $28.95 million.

Sanara MedTech Trading Up 0.3%

NASDAQ SMTI opened at $32.17 on Wednesday. The firm has a 50 day simple moving average of $34.42 and a 200-day simple moving average of $25.61. The company has a debt-to-equity ratio of 5.86, a quick ratio of 2.30 and a current ratio of 2.58. Sanara MedTech has a one year low of $16.05 and a one year high of $35.52. The firm has a market cap of $295.64 million, a price-to-earnings ratio of 145.77 and a beta of 1.23.

Analyst Ratings Changes

SMTI has been the topic of a number of research reports. Weiss Ratings upgraded shares of Sanara MedTech from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Wall Street Zen downgraded shares of Sanara MedTech from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 1st. Lake Street Capital downgraded shares of Sanara MedTech from a “buy” rating to a “hold” rating and set a $35.00 price target for the company. in a research note on Thursday, July 30th. Freedom Capital lowered Sanara MedTech from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 3rd. Finally, HC Wainwright cut Sanara MedTech from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $36.00 to $35.00 in a research note on Thursday, July 30th. Four analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus price target of $35.00.

Sanara MedTech Company Profile

Sanara MedTech Inc is a medical technology company focused on developing, commercializing and distributing products used in wound care, surgical soft-tissue repair and tissue regeneration. The company serves healthcare providers treating acute, chronic and complex wounds, as well as patients requiring surgical tissue management.

Sanara’s product portfolio includes advanced wound-care and tissue-repair technologies such as CellerateRX products, FORTIFY tissue-repair products and other regenerative medicine solutions.